A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Recruiting · NCT07106671 · Registry updated 2025-08-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma | Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, neoplasm, plasma cell neoplasm | Recruiting | Phase 2 | 2025-08-06 | NCT07106671 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences | Tianjin | China | 10 |